Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUMETANIDE vs FUROSCIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
Treatment of edema associated with congestive heart failure,Treatment of edema associated with cirrhosis of the liver,Treatment of edema associated with renal disease including nephrotic syndrome
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Terminal half-life 1.5-2 hours in healthy; prolonged to 4-8 hours in renal impairment (Cr Cl <30 m L/min) and 9-19 hours in anuria
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Furosemide is primarily metabolized by glucuronidation via UGT1A1, UGT1A9, and UGT2B7; to a lesser extent by cytochrome P450 enzymes.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Renal (60-80% unchanged; glucuronide metabolites account for 10-20%); biliary/fecal (<10%)
Approximately 95% bound, primarily to albumin.
91-99%, primarily to albumin
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
0.1-0.2 L/kg; higher in neonates (0.2-0.4 L/kg); restricted to extracellular fluid in adults
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
Subcutaneous: 99% compared to IV; oral: 60-70% (variable due to first-pass metabolism)
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
e GFR 15-29 m L/min/1.73m2: 40 mg subcutaneously once daily. e GFR <15 m L/min: not recommended. e GFR ≥30: no adjustment needed.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A or B: no adjustment. Child-Pugh C: use with caution; reduce dose to 40 mg subcutaneously once daily. No specific pharmacokinetic data in severe impairment.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
Safety and efficacy not established in pediatric patients (<18 years). No approved dosing available.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
Start at 40 mg subcutaneously once daily. Monitor renal function and electrolyte levels closely. Consider lower doses due to age-related decreased renal function.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
Furosemide can cause profound diuresis with water and electrolyte depletion, leading to serious adverse events such as circulatory collapse and thromboembolic complications. Careful medical supervision is required.
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Monitor for electrolyte disturbances (e.g., hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia),May cause ototoxicity, especially with rapid injection or high doses,Risk of renal impairment; monitor renal function,Can exacerbate systemic lupus erythematosus,Avoid in patients with known sulfonamide allergy
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
Anuria,Severe hypokalemia,Severe hyponatremia,Hypersensitivity to furosemide or sulfonamides,Hepatic coma or pre-coma
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
Avoid foods high in sodium (e.g., processed meats, canned soups) to reduce fluid retention. No significant food-drug interactions. May increase potassium and magnesium loss; ensure adequate intake of potassium-rich foods (e.g., bananas, oranges) but monitor levels closely.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause maternal hypovolemia, reduced placental perfusion, and fetal oligohydramnios; avoid if possible. Not associated with major congenital malformations.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
Furosemide is excreted into human breast milk in low amounts (M/P ratio approximately 0.2-0.5). Peak milk concentration ~0.4-0.6 µg/m L after 40 mg oral dose. Limited data suggest no adverse effects in breastfed infants. Use with caution, especially in neonates due to risk of diuresis and electrolyte imbalance.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
Furosemide pharmacokinetics may be altered in pregnancy due to increased volume of distribution and renal clearance. Lower doses may achieve desired diuresis; start at low end of dosing range (20-40 mg/day oral) and titrate based on clinical response and monitoring. Avoid high doses and prolonged use due to risk of hypovolemia and placental hypoperfusion.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
FUROSCIX (furosemide) is a subcutaneous loop diuretic for heart failure congestion. Onset of diuresis within 30 minutes; peak effect at 1-2 hours. Monitor for hypokalemia, hypomagnesemia, and ototoxicity. Use with caution in sulfonamide allergy. Avoid concurrent use with NSAIDs as they reduce diuretic efficacy.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
Inject subcutaneously into the abdomen; rotate sites.,Take in the morning to avoid nocturia.,Monitor daily weight and report >2 lb/day gain.,Report hearing changes, ringing in ears, or dizziness.,Avoid excessive salt intake; limit alcohol.,Do not use with NSAIDs or lithium without doctor approval.
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUMETANIDE vs FUROSCIX, answered by our medical review team.
BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. FUROSCIX is a Loop Diuretic that works by Furosemide inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing sodium and chloride reabsorption, leading to increased diuresis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUMETANIDE and FUROSCIX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. The standard adult dose of FUROSCIX is: 80 mg subcutaneously once daily via prefilled syringe. Maximum 80 mg/day. Administer as an adjunct to oral diuretic therapy.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUMETANIDE and FUROSCIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. FUROSCIX is classified as Category C. Furosemide crosses the placenta. First trimester: Limited human data, animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.